In vitro and in vivo correlation for lipid-based formulations: Current status and future perspectives

In vitro and in vivo correlation for lipid-based formulations: Current status and future perspectives

Authors: Huang Y, Yu Q, Chen Z, Wu W, Zhu Q, Lu Y
Publication: Acta Pharm Sin B
Software: GastroPlus®
Division: PBPK

Lipid-based formulations (LBFs) have demonstrated a great potential in enhancing the oral absorption of poorly water-soluble drugs.

A comprehensive review of integrative pharmacology-based investigation: A paradigm shift in traditional Chinese medicine

A comprehensive review of integrative pharmacology-based investigation: A paradigm shift in traditional Chinese medicine

Publication: Acta Pharm Sin B
Software: GastroPlus®
Division: PBPK

Over the past decade, traditional Chinese medicine (TCM) has widely embraced systems biology and its various data integration approaches to promote its modernization.

A Survey of the Regulatory Requirements for the Waiver of In Vivo Bioequivalence Studies of Generic Products in Certain Dosage Forms by Participating Regulators and Organisations of the International Pharmaceutical Regulators Programme

A Survey of the Regulatory Requirements for the Waiver of In Vivo Bioequivalence Studies of Generic Products in Certain Dosage Forms by Participating Regulators and Organisations of the International Pharmaceutical Regulators Programme

Publication: J Pharm Pharm Sci
Division: PBPK

The requirements to waive in vivo bioequivalence studies for immediate release solid oral dosage forms based on the Biopharmaceutics Classifications System (BCS) are well known, and biowaivers[1] for other types of oral dosage forms based on pre-defined criteria may also be acceptable.

Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs

Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs

Publication: Mol Pharm
Software: GastroPlus®
Division: PBPK

Colon absorption is a key determinant for the successful development of modified-release (MR) formulations, and the risk that colon absorption may limit the in vivo performance...

An IPRP survey of the regulatory requirements for the waiver of in vivo bioequivalence studies of generic medicinal products in certain dosage forms

An IPRP survey of the regulatory requirements for the waiver of in vivo bioequivalence studies of generic medicinal products in certain dosage forms

Publication: J Pharm Pharm Sci

The requirements to waive in vivo bioequivalence studies for immediate release solid oraldosage forms based on the Biopharmaceutics Classifications System (BCS) are well known, and biowaiversafor other types of oral dosage forms based on pre-defined criteria may also be acceptable.

Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains

Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains

Publication: bioRxiv

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) transmission with several emerging variants remain uncontrolled in many countries, indicating the pandemic remains severe.

Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare

Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare

Publication: Front Med (Lausanne)
Software: GastroPlus®
Division: PBPK

A thorough understanding of the behavior of drug formulations in the human gastrointestinal (GI) tract is essential when working in the field of oral drug development in a pharmaceutical company.

Prediction of Plasma Concentrations Using In Silico Modeling and Simulation Approach: Case of Acebutolol

Prediction of Plasma Concentrations Using In Silico Modeling and Simulation Approach: Case of Acebutolol

Authors: Bokri E, Felfel H, Bahri S
Publication: Ann Pharm Fr
Software: GastroPlus®
Division: PBPK

The aim of this study was to predict the plasma concentrations of acebutolol tablets with different dissolution profiles using computer modelling and evaluating whether they are bioequivalent using simulated population studies.

Understanding Carrier Performance in Low-Dose Dry Powder Inhalation: An In Vitro–In Silico Approach

Understanding Carrier Performance in Low-Dose Dry Powder Inhalation: An In Vitro–In Silico Approach

Publication: Pharmaceutics
Software: GastroPlus®

The use of physiologically based pharmacokinetic (PBPK) models to support drug product development has become increasingly popular.

Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration

Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration

Publication: J Med Chem
Software: ADMET Predictor®

Developing in silico models to predict the brain penetration of drugs remains a challenge owing to the intricate involvement of multiple transport systems in the blood brain barrier, and the necessity to consider a...

A PK/PD model of saxagliptin: to simulate its pharmacokinetics and pharmacodynamics in healthy adults and patients with impaired hepatic function

A PK/PD model of saxagliptin: to simulate its pharmacokinetics and pharmacodynamics in healthy adults and patients with impaired hepatic function

Authors: Shi L, Miao F, Wang G, Sun W, Liu Y
Publication: Journal of Chinese Pharmaceutical Sciences
Software: GastroPlus®

In this study, we aimed to develop and evaluate a whole-body physiologically based pharmacokinetic (WB-PBPK)/pharmacodynamic (PD) model for...